Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SECUKINUMAB Cause Maternal exposure timing unspecified? 301 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 301 reports of Maternal exposure timing unspecified have been filed in association with SECUKINUMAB (COSENTYX). This represents 0.2% of all adverse event reports for SECUKINUMAB.

301
Reports of Maternal exposure timing unspecified with SECUKINUMAB
0.2%
of all SECUKINUMAB reports
223
Deaths
240
Hospitalizations

How Dangerous Is Maternal exposure timing unspecified From SECUKINUMAB?

Of the 301 reports, 223 (74.1%) resulted in death, 240 (79.7%) required hospitalization, and 241 (80.1%) were considered life-threatening.

Is Maternal exposure timing unspecified Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for SECUKINUMAB. However, 301 reports have been filed with the FAERS database.

What Other Side Effects Does SECUKINUMAB Cause?

Drug ineffective (27,434) Psoriasis (21,976) Pain (15,244) Arthralgia (13,769) Fatigue (9,406) Psoriatic arthropathy (8,900) Pruritus (8,755) Malaise (8,570) Rash (8,023) Condition aggravated (7,536)

What Other Drugs Cause Maternal exposure timing unspecified?

RITUXIMAB (402) METHOTREXATE (350) ADALIMUMAB (343) DICLOFENAC (331) TOCILIZUMAB (327) HYDROXYCHLOROQUINE (309) FOLIC ACID (304) INFLIXIMAB (303) LEFLUNOMIDE (302) OXYCODONE (300)

Which SECUKINUMAB Alternatives Have Lower Maternal exposure timing unspecified Risk?

SECUKINUMAB vs SELADELPAR LYSINE SECUKINUMAB vs SELEGILINE SECUKINUMAB vs SELENIUM SECUKINUMAB vs SELENIUM SULFIDE SECUKINUMAB vs SELEXIPAG

Related Pages

SECUKINUMAB Full Profile All Maternal exposure timing unspecified Reports All Drugs Causing Maternal exposure timing unspecified SECUKINUMAB Demographics